BiotechTube
Home/Pipeline/ChemGem™ (Gemcitabine)

ChemGem™ (Gemcitabine)

Pancreatic Cancer

Pre-clinicalActive

Key Facts

Indication
Pancreatic Cancer
Phase
Pre-clinical
Status
Active
Company
OncoLize

About OncoLize

OncoLize is a private, pre-clinical stage biotech developing an injectable polymer-based hydrogel platform (ChemoGell™) for the intratumoral delivery of proven chemotherapy drugs. The technology aims to concentrate drugs inside the tumor, enhancing efficacy and minimizing systemic toxicity. Having secured €1.6M in seed funding and demonstrated promising preclinical results, including 100% survival in a pancreatic cancer PDX model, the company is preparing for a Series A round of €8-10M in late 2024 to advance into clinical trials by 2026.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b